Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22351987 | 1.00 | BCHE (0.51) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20786522 | 0.89 | BCHE (0.52) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20927100 | 0.89 | BCHE (0.52) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20782393 | 0.88 | BCHE (0.51) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20927136 | 0.88 | BCHE (0.51) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20792377 | 0.88 | BCHE (0.51) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20785732 | 0.88 | BCHE (0.51) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL21540010 | 0.87 | ADA (0.52) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL23516968 | 0.86 | BCHE (0.57) | BCHEADANFKB1BLMMAPK1 | |
| SCHEMBL20624631 | 0.86 | BCHE (0.57) | BCHEADANFKB1BLMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3546473-A1 | CYCLIC [(2',5')P(3',5')P]-DINUCLEOTIDES FOR CYTOKINE INDUCTION | Kayla Therapeutics (FR) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019079261-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130295-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | RAD18, MVD, USP18 | BCHE 1875/4885ADA 1979/4885NFKB1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.